Free Trial

VolitionRx (NYSE:VNRX) Given Buy Rating at D. Boral Capital

VolitionRx logo with Medical background

D. Boral Capital restated their buy rating on shares of VolitionRx (NYSE:VNRX - Free Report) in a research report sent to investors on Wednesday morning,Benzinga reports. The firm currently has a $5.00 price objective on the stock.

Several other research firms have also recently issued reports on VNRX. Jones Trading upgraded VolitionRx to a "strong-buy" rating and set a $3.00 target price on the stock in a research report on Tuesday, June 10th. Wall Street Zen assumed coverage on VolitionRx in a research report on Thursday, May 15th. They set a "sell" rating on the stock. Finally, HC Wainwright assumed coverage on VolitionRx in a research report on Tuesday, April 8th. They set a "buy" rating and a $2.50 target price on the stock. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $3.50.

Check Out Our Latest Analysis on VNRX

VolitionRx Trading Up 2.9%

Shares of VNRX traded up $0.02 during mid-day trading on Wednesday, hitting $0.68. 91,836 shares of the company's stock were exchanged, compared to its average volume of 207,269. VolitionRx has a fifty-two week low of $0.40 and a fifty-two week high of $0.94. The firm has a market capitalization of $70.71 million, a P/E ratio of -1.89 and a beta of 1.20. The business's 50 day moving average is $0.61 and its two-hundred day moving average is $0.58.

Hedge Funds Weigh In On VolitionRx

Hedge funds and other institutional investors have recently bought and sold shares of the company. Lagoda Investment Management L.P. lifted its holdings in shares of VolitionRx by 24.3% in the fourth quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company's stock valued at $4,546,000 after purchasing an additional 1,481,000 shares in the last quarter. Millennium Management LLC purchased a new stake in shares of VolitionRx in the fourth quarter valued at about $36,000. Silverberg Bernstein Capital Management LLC lifted its holdings in shares of VolitionRx by 42.8% in the second quarter. Silverberg Bernstein Capital Management LLC now owns 200,782 shares of the company's stock valued at $153,000 after purchasing an additional 60,209 shares in the last quarter. Two Sigma Securities LLC purchased a new stake in shares of VolitionRx in the fourth quarter valued at about $29,000. Finally, Northern Trust Corp lifted its holdings in shares of VolitionRx by 32.0% in the fourth quarter. Northern Trust Corp now owns 117,875 shares of the company's stock valued at $71,000 after purchasing an additional 28,579 shares in the last quarter. 8.09% of the stock is owned by institutional investors and hedge funds.

About VolitionRx

(Get Free Report)

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.

Read More

Should You Invest $1,000 in VolitionRx Right Now?

Before you consider VolitionRx, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and VolitionRx wasn't on the list.

While VolitionRx currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Don’t Miss These Top 3 Defense Stocks Set To Gain
Triple-Digit Gains: These 4 Nuclear Stocks Have Even More Upside Ahead
3 Made in America Stocks Under $20 You Need to See!

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines